Business
Atea is a clinical-stage antiviral company focused on HCV and HEV candidates, including the bemnifosbuvir and ruzasvir regimen for HCV.
Atea remained pre-revenue in FY2025, but losses and cash burn improved while equity fell and buybacks resumed.
The read at a glance✓ Audited against SEC data
- Business mix — Antiviral clinical pipelineNote
- Revenue — No revenue taggedNote
- Losses — Net loss narrowed to $158.3MOK
- Cash — Cash from ops improvedOK
- Capital — Equity fell 37.2%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — FY2021 Altman-Z safe; current screen unavailableNote
Where the revenue comes from
Fiscal 2021, as Atea Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Roche License Agreement$351.4M
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-06-22
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Atea Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.